CXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Crane NXT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to enter now. The stock has solid revenue growth and a stable dividend, but the current price action is weak, momentum is bearish, options sentiment is not strongly supportive, and analysts have recently cut price targets. I would not buy at this moment; I would wait for a clearer technical reversal or a better entry point.
CXT is in a bearish trend. The MACD histogram is negative and worsening, RSI_6 at 41.46 shows weak but not oversold momentum, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price closed at 43.35, below the pivot of 44.767 and near support at 43.659, with deeper support at 42.975. This suggests downside pressure remains intact and the stock has not yet confirmed a reversal.
Q1 2026 revenue rose 17.4% year-over-year to $387.7 million, with about 6% organic sales growth. The company also declared a quarterly dividend of $0.18, showing continued cash generation. Oppenheimer noted fundamentals remain healthy and pointed to potential benefit from a new $10 banknote launch and international wins.
GAAP EPS missed expectations at $0.11, net income fell 70.5% year-over-year, EPS dropped 70.3%, and gross margin declined to 40.21%. Analyst price targets have been cut by multiple firms, including Oppenheimer, Northland, UBS, and Baird. Recent price trend is weak, with the stock down on the day and near short-term support.
Latest quarter: Q1 2026. Revenue was strong, up 17.38% year-over-year to $387.7 million, which is the main positive. However, profitability weakened sharply: net income fell to $6.4 million, EPS dropped to $0.11, and gross margin declined to 40.21%. This is a growth-positive but earnings-quality-negative quarter.
Analyst sentiment is mixed to cautious. Baird and Oppenheimer still have Outperform ratings, but both lowered price targets, and Northland cut its target while keeping a Market Perform rating. UBS also lowered its target. Overall, Wall Street sees the long-term story as intact, but near-term expectations have become more conservative.
